{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:18:06Z","timestamp":1763198286347,"version":"3.45.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,15]]},"DOI":"10.7759\/cureus.96886","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:14:53Z","timestamp":1763198093000},"source":"Crossref","is-referenced-by-count":0,"title":["Direct Renin Inhibition With Aliskiren Compared to Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Hypertension: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Abubakar","family":"Gapizov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivam","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavna","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Kumawat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":".","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulqurnain","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills KT","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020, 16:223-37. 10.1038\/s41581-019-0244-2","journal-title":"Nat Rev Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61020193","article-title":"Key updates to the 2024 ESC Hypertension Guidelines and Future Perspectives","volume":"61","author":"Burlacu A","year":"2025","unstructured":"Burlacu A, Kuwabara M, Brinza C, Kanbay M. Key updates to the 2024 ESC Hypertension Guidelines and Future Perspectives. Medicina (Kaunas). 2025, 61:10.3390\/medicina61020193","journal-title":"Medicina (Kaunas)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111426","article-title":"The renin-angiotensin-aldosterone system: an old tree sprouts new shoots","volume":"124","author":"Ruan Y","year":"2024","unstructured":"Ruan Y, Yu Y, Wu M, Jiang Y, Qiu Y, Ruan S. The renin-angiotensin-aldosterone system: an old tree sprouts new shoots. Cell Signal. 2024, 124:111426. 10.1016\/j.cellsig.2024.111426","journal-title":"Cell Signal"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-024-00381-6","article-title":"ACE inhibitors and angiotensin receptor blockers for the primary and secondary prevention of cardiovascular outcomes: recommendations from the 2024 Egyptian Cardiology Expert Consensus in collaboration with the CVREP Foundation","volume":"13","author":"Sobhy M","year":"2024","unstructured":"Sobhy M, Eletriby A, Ragy H, et al.. ACE inhibitors and angiotensin receptor blockers for the primary and secondary prevention of cardiovascular outcomes: recommendations from the 2024 Egyptian Cardiology Expert Consensus in collaboration with the CVREP Foundation. Cardiol Ther. 2024, 13:707-36. 10.1007\/s40119-024-00381-6","journal-title":"Cardiol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/2042018813490779","article-title":"The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient","volume":"4","author":"Riccioni G","year":"2013","unstructured":"Riccioni G. The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient. Ther Adv Endocrinol Metab. 2013, 4:139-45. 10.1177\/2042018813490779","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2716-0","article-title":"Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases","volume":"29","author":"Nadeem S","year":"2014","unstructured":"Nadeem S, Batisky DL. Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases. Pediatr Nephrol. 2014, 29:2105-11. 10.1007\/s00467-013-2716-0","journal-title":"Pediatr Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19382","article-title":"Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis","volume":"8","author":"Fu S","year":"2017","unstructured":"Fu S, Wen X, Han F, Long Y, Xu G. Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis. Oncotarget. 2017, 8:89364-74. 10.18632\/oncotarget.19382","journal-title":"Oncotarget"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01442-z","article-title":"Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews","volume":"20","author":"Zhao Q","year":"2020","unstructured":"Zhao Q, Shen J, Lu J, Jiang Q, Wang Y. Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews. BMC Cardiovasc Disord. 2020, 20:179. 10.1186\/s12872-020-01442-z","journal-title":"BMC Cardiovasc Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/10641963.2016.1200064","article-title":"Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease","volume":"38","author":"Uneda K","year":"2016","unstructured":"Uneda K, Tamura K, Wakui H, et al.. Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease. Clin Exp Hypertens. 2016, 38:738-43. 10.1080\/10641963.2016.1200064","journal-title":"Clin Exp Hypertens"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164936","article-title":"Comparative effects of direct renin inhibitor and angiotensin receptor blocker on albuminuria in hypertensive patients with type 2 diabetes. A randomized controlled trial","volume":"11","author":"Uzu T","year":"2016","unstructured":"Uzu T, Araki SI, Kashiwagi A, et al.. Comparative effects of direct renin inhibitor and angiotensin receptor blocker on albuminuria in hypertensive patients with type 2 diabetes. A randomized controlled trial. PLoS One. 2016, 11:e0164936. 10.1371\/journal.pone.0164936","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1470320314530018","article-title":"Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria","volume":"16","author":"Imbalzano E","year":"2015","unstructured":"Imbalzano E, Scarpelli M, Mandraffino G, et al.. Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. J Renin Angiotensin Aldosterone Syst. 2015, 16:956-64. 10.1177\/1470320314530018","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169258","article-title":"Effects of direct renin blockade on renal & systemic hemodynamics and on RAAS activity, in weight excess and hypertension: a randomized clinical trial","volume":"12","author":"Kwakernaak AJ","year":"2017","unstructured":"Kwakernaak AJ, Roksnoer LC, Lambers Heerspink HJ, et al.. Effects of direct renin blockade on renal & systemic hemodynamics and on RAAS activity, in weight excess and hypertension: a randomized clinical trial. PLoS One. 2017, 12:e0169258. 10.1371\/journal.pone.0169258","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12725","article-title":"Two-year outcomes of patients treated with aliskiren under clinical practice conditions: non-interventional prospective study","volume":"18","author":"Zeymer U","year":"2016","unstructured":"Zeymer U, Dechend R, Riemer T, Deeg E, Senges J, Pittrow D, Schmieder R. Two-year outcomes of patients treated with aliskiren under clinical practice conditions: non-interventional prospective study. J Clin Hypertens (Greenwich). 2016, 18:647-54. 10.1111\/jch.12725","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-021-00168-0","article-title":"Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19","volume":"27","author":"Kang SH","year":"2021","unstructured":"Kang SH, Lee DH, Han KD, et al.. Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19. Clin Hypertens. 2021, 27:11. 10.1186\/s40885-021-00168-0","journal-title":"Clin Hypertens"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving HH","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, et al.. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012, 367:2204-13. 10.1056\/NEJMoa1208799","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1003852","article-title":"Advances in pathogenesis and treatment of essential hypertension","volume":"9","author":"Ma J","year":"2022","unstructured":"Ma J, Chen X. Advances in pathogenesis and treatment of essential hypertension. Front Cardiovasc Med. 2022, 9:1003852. 10.3389\/fcvm.2022.1003852","journal-title":"Front Cardiovasc Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12828","article-title":"Benefits and risks of aliskiren treatment in patients with type 2 diabetes: analyses of the 3A registry","volume":"18","author":"Kistner I","year":"2016","unstructured":"Kistner I, Zeymer U, Dechend R, et al.. Benefits and risks of aliskiren treatment in patients with type 2 diabetes: analyses of the 3A registry. J Clin Hypertens (Greenwich). 2016, 18:1045-53. 10.1111\/jch.12828","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6060061","article-title":"Renin inhibition with aliskiren: a decade of clinical experience","volume":"6","author":"Pantzaris ND","year":"2017","unstructured":"Pantzaris ND, Karanikolas E, Tsiotsios K, Velissaris D. Renin inhibition with aliskiren: a decade of clinical experience. J Clin Med. 2017, 6: 61. 10.3390\/jcm6060061","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2017.1313447","article-title":"Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease","volume":"49","author":"Antlanger M","year":"2017","unstructured":"Antlanger M, Bernhofer S, Kovarik JJ, et al.. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease. Ann Med. 2017, 49:525-33. 10.1080\/07853890.2017.1313447","journal-title":"Ann Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/422462-direct-renin-inhibition-with-aliskiren-compared-to-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-in-hypertension-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:14:53Z","timestamp":1763198093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/422462-direct-renin-inhibition-with-aliskiren-compared-to-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-in-hypertension-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.96886","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,15]]}}}